Tecfidera

Upcoming events – key tests approach for Biogen and Kalvista
Upcoming events – key tests approach for Biogen and Kalvista
EP Vantage
Biogen
BIIB098
Tecfidera
multiple sclerosis
KalVista
HAE
Biocryst
BCX7353
KVD900
Flag link:
After Alzheimer’s collapse, Biogen must win Tecfidera patent challenge
After Alzheimer’s collapse, Biogen must win Tecfidera patent challenge
EP Vantage
Biogen
Alzheimer's disease
Tecfidera
generics
Mylan
Flag link:
14 Drugs Earn Billions for These Massachusetts Biotechs
14 Drugs Earn Billions for These Massachusetts Biotechs
BioSpace
Massachusetts
Boston
Biogen
Tecfidera
Benepali
Shire
Takeda
Vyvanse
Vertex Pharmaceuticals
Orkambi
Kalydeco
Alexion
Soliris
Strensiq
Sanofi Genzyme
Lantus
Ironwood Pharmaceuticals
Linzess
Flag link:
New insight into how Biogen's Tecfidera works may lead to better MS therapies
New insight into how Biogen's Tecfidera works may lead to better MS therapies
Fierce Biotech
Biogen
Tecfidera
MS
multiple sclerois
R&D
Flag link:
Mylan takes step toward knocking down key patent for Biogen's top-seller
Mylan takes step toward knocking down key patent for Biogen's top-seller
Biopharma Dive
Mylan
Biogen
Tecfidera
patents
inter partes review
Flag link:
Forward Pharma loses appeal in Tecfidera patent dispute with Biogen
Forward Pharma loses appeal in Tecfidera patent dispute with Biogen
Reuters
Biogen
Tecfidera
MS
Forward Pharma
Flag link:
What's beyond hepatitis C in the drug launch hit parade? Ibrance and Tecfidera, for two
What's beyond hepatitis C in the drug launch hit parade? Ibrance and Tecfidera, for two
Fierce Pharma
drug launches
hepatitis C
Ibrance
Tecfidera
Biogen
Pfizer
Gilead Sciences
Flag link:
How Biogen Inc. Makes Most of Its Money
How Biogen Inc. Makes Most of Its Money
Motley Fool
Biogen
Tecfidera
Tysabri
MS
multiple sclerosis
Flag link:
Biogen aims to block Tecfidera generics with flurry of lawsuits
Biogen aims to block Tecfidera generics with flurry of lawsuits
Bizjournals.com
Biogen
Tecfidera
generics
MS
multiple sclerosis
Novartis
Sandoz
Mylan Labs
Flag link:
Why Roche's New Drug Is Bad News For Biogen
Why Roche's New Drug Is Bad News For Biogen
Barron's
Roche
Biogen
Ocrevus
multiple sclerosis
MS
Tysabri
Tecfidera
Flag link:
Forward Pharma Intends to Appeal Decision in Patent Interference Proceeding with Biogen Inc.
Forward Pharma Intends to Appeal Decision in Patent Interference Proceeding with Biogen Inc.
Yahoo
Biogen
Tecfidera
patents
Forward Pharma
MS
multiple sclerosis
Flag link:
Biogen Wins Tecfidera Patent Case
Biogen Wins Tecfidera Patent Case
Investopedia
Biogen
Tecfidera
patents
Kyle Bass
MS
multiple sclerosis
Flag link:
If copies of Teva's Copaxone hit, oral MS rivals could be the real threat
If copies of Teva's Copaxone hit, oral MS rivals could be the real threat
Fierce Pharma
Teva Pharmaceutical
Copaxone
MS
multiple sclerosis
generics
Tecfidera
Biogen
Gilenya
Novartis
Aubagio
Sanofi
Flag link:
Biogen profit drops 22 pct due to Tecfidera-related costs
Biogen profit drops 22 pct due to Tecfidera-related costs
Yahoo/Reuters
Biogen
earnings
Tecfidera
Flag link:
Biogen to pay $1.25B settlement in multiple sclerosis drug case
Biogen to pay $1.25B settlement in multiple sclerosis drug case
Bizjournals.com
Biogen
Tecfidera
Forward Pharma
MS
multiple sclerosis
patents
Flag link:
Biogen recruits Jamie-Lynn Sigler for Tecfidera campaign
Biogen recruits Jamie-Lynn Sigler for Tecfidera campaign
Medical Marketing and Media
Biogen
celebrity endorsements
Tecfidera
MS
multiple sclerosis
Flag link:
Biogen may have edge in high-stakes Tecfidera patent battle, analyst says
Biogen may have edge in high-stakes Tecfidera patent battle, analyst says
Bizjournals.com
Biogen
Tecfidera
MS
multiple sclerosis
patents
Forward Pharma
Flag link:
Biogen's Tecfidera faces outside pressure
Biogen's Tecfidera faces outside pressure
BioPharma Dive
Biogen
Tecfidera
multiple sclerosis
MS
patents
Forward Pharma
Flag link:
What puts a new drug launch in line for victory? Ask Gilead, Biogen and J&J
What puts a new drug launch in line for victory? Ask Gilead, Biogen and J&J
Fierce Pharma
Gilead Sciences
Biogen
JNJ
drug launches
AbbVie
Sovaldi
Imbruvica
Tecfidera
Flag link:
Biogen’s Tecfidera, Amgen’s Enbrel tell a tale of pricing power and weakness
Biogen’s Tecfidera, Amgen’s Enbrel tell a tale of pricing power and weakness
Fierce Pharma
Biogen
Tecfidera
Amgen
Enbrel
drug pricing
Flag link:

Pages